Cargando…

Corrigendum: Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades

Detalles Bibliográficos
Autores principales:	Chen, Hao, Chong, Wei, Wu, Qian, Yao, Yueliang, Mao, Min, Wang, Xin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6614515/ https://www.ncbi.nlm.nih.gov/pubmed/31312207 http://dx.doi.org/10.3389/fimmu.2019.01523

Ejemplares similares

Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades
por: Chen, Hao, et al.
Publicado: (2019)

Correlation between LRP1B Mutations and Tumor Mutation Burden in Gastric Cancer
por: Hu, Sizhe, et al.
Publicado: (2021)

Genomic landscape of the immunogenicity regulation in skin melanomas with diverse tumor mutation burden
por: Georgoulias, George, et al.
Publicado: (2022)

Dose-Dependent Effect of Tumor Mutation Burden on Cancer Prognosis Following Immune Checkpoint Blockade: Causal Implications
por: Zheng, Ming
Publicado: (2022)

Retracted: Correlation between LRP1B Mutations and Tumor Mutation Burden in Gastric Cancer
por: Methods in Medicine, Computational and Mathematical
Publicado: (2023)

Novel Immune Check-Point Regulators in Tolerance Maintenance
por: Guo, Yanxia, et al.
Publicado: (2015)

LRP1B mutation associates with increased tumor mutation burden and inferior prognosis in liver hepatocellular carcinoma
por: Yu, Ge, et al.
Publicado: (2022)

Association Analyses of TP53 Mutation With Prognosis, Tumor Mutational Burden, and Immunological Features in Acute Myeloid Leukemia
por: Wen, Xiang-mei, et al.
Publicado: (2021)

Erratum: Novel Immune Check-Point Regulators in Tolerance Maintenance
Publicado: (2016)

Co-Mutation of FAT3 and LRP1B in Lung Adenocarcinoma Defines a Unique Subset Correlated With the Efficacy of Immunotherapy
por: Zhu, Mingyu, et al.
Publicado: (2022)

LRP1B or TP53 mutations are associated with higher tumor mutational burden and worse survival in hepatocellular carcinoma
por: Wang, Longrong, et al.
Publicado: (2021)

LRP1B mutation: a novel independent prognostic factor and a predictive tumor mutation burden in hepatocellular carcinoma
por: Liu, Fahui, et al.
Publicado: (2021)

Corrigendum: The Significance of Transarterial Chemo(embolization) Combined With Tyrosine Kinase Inhibitors and Immune Check Point Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review
por: Ke, Qiao, et al.
Publicado: (2022)

Influence of T Cell-Mediated Immune Surveillance on Somatic Mutation Occurrences in Melanoma
por: Jiang, Chongming, et al.
Publicado: (2022)

Multi-faceted role of LRP1 in the immune system
por: Sizova, Olga, et al.
Publicado: (2023)

Successful Treatment of Advanced Intrahepatic Cholangiocarcinoma With a High Tumor Mutational Burden and PD-L1 Expression by PD-1 Blockade Combined With Tyrosine Kinase Inhibitors: A Case Report
por: Zhang, Ze, et al.
Publicado: (2021)

Significance of Tumor Mutation Burden in Immune Infiltration and Prognosis in Cutaneous Melanoma
por: Kang, Kai, et al.
Publicado: (2020)

ARID1A, ARID1B, and ARID2 Mutations Serve as Potential Biomarkers for Immune Checkpoint Blockade in Patients With Non-Small Cell Lung Cancer
por: Zhu, Guangsheng, et al.
Publicado: (2021)

Editorial: Improvement of melanoma immune checkpoint blockade therapy with potential combinatorial regiments
por: Wang, Xueyan, et al.
Publicado: (2022)

Novel LRP6 Mutations Causing Non-Syndromic Oligodontia
por: Lee, Yejin, et al.
Publicado: (2022)

The immune response‐related mutational signatures and driver genes in non‐small‐cell lung cancer
por: Chen, Hao, et al.
Publicado: (2019)

Cutaneous Melanoma: Mutational Status and Potential Links to Tertiary Lymphoid Structure Formation
por: Salem, Deepak, et al.
Publicado: (2021)

NOTCH4 mutation as predictive biomarker for immunotherapy benefits in NRAS wildtype melanoma
por: Li, Hongxia, et al.
Publicado: (2022)

Corrigendum: Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study
por: Queirolo, Paola, et al.
Publicado: (2018)

Clinical relevance of genetic polymorphisms in WNT signaling pathway (SFRP1, WNT3A, CTNNB1, WIF-1, DKK-1, LRP5, LRP6) on pulmonary tuberculosis in a Chinese population
por: Huang, Qian, et al.
Publicado: (2022)

Role of exosomes in non-small cell lung cancer and EGFR-mutated lung cancer
por: Rao, Ding-Yu, et al.
Publicado: (2023)

Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better
por: Zheng, Ming
Publicado: (2022)

Effect of Immune Checkpoint Blockade on Myeloid-Derived Suppressor Cell Populations in Patients With Melanoma
por: Sun, Steven H., et al.
Publicado: (2021)

Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma
por: Loo, Kimberly, et al.
Publicado: (2022)

B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint Blockade
por: Singh, Shubhra, et al.
Publicado: (2022)

The Predictive Value of MAP2K1/2 Mutations on Efficiency of Immunotherapy in Melanoma
por: Ye, Ting, et al.
Publicado: (2022)

A specific immune signature for predicting the prognosis of glioma patients with IDH1-mutation and guiding immune checkpoint blockade therapy
por: Zeng, Zhirui, et al.
Publicado: (2022)

Incidence and factors associated with cutaneous immune-related adverse events to immune check point inhibitors: An ambispective cohort study
por: Luangnara, Athitaya, et al.
Publicado: (2022)

Checks and Balances in Autoimmune Vasculitis
por: Hid Cadena, Rebeca, et al.
Publicado: (2018)

Landscape of Infiltrated Immune Cell Characterization in Uveal Melanoma to Improve Immune Checkpoint Blockade Therapy
por: Lv, Xiaohui, et al.
Publicado: (2022)

CheckMate-915: does adjuvant CTLA-4 blockade play a role in resected melanoma?
por: Su, David, et al.
Publicado: (2023)

Homologous recombination repair gene mutations as a predictive biomarker for immunotherapy in patients with advanced melanoma
por: You, Zhixuan, et al.
Publicado: (2022)

Adjuvant immunotherapy for cancer: both dendritic cell-priming and check-point inhibitor blockade are required for immunotherapy
por: SEYA, Tsukasa, et al.
Publicado: (2018)

The genetic heterogeneity and mutational burden of engineered melanomas in zebrafish models
por: Yen, Jennifer, et al.
Publicado: (2013)

Pre-treatment serum albumin and mutational burden as biomarkers of response to immune checkpoint blockade
por: Yoo, Seong-Keun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5lbfsehs53j7h1n288uo4pk0p2